Pharmaceutical - Pharmaceutical, Durect

Filter

Current filters:

PharmaceuticalDurect

Popular Filters

Impax and DURECT in $63 million deal for Eladur pain patch

07-01-2014

US specialty drugmaker Impax Laboratories has entered into an agreement with fellow USA-based DURECT…

DurectEladurGlobalImpax LaboratoriesLicensingNeurologicalPharmaceutical

US FDA accepts DURECT's NDA for Posidur

20-06-2013

DURECT Corp (Nasdaq: DRRX) says that the New Drug Application for its investigational product Posidur…

DurectNeurologicalNorth AmericaPharmaceuticalPosidurRegulation

Lilly drops enzastaurin development; Remoxy future viewed by Pfizer and partners

10-05-2013

US drug major Eli Lilly (NYSE: LLY) revealed that Phase III clinical trial results from enzastaurin's…

DurectEli LillyenzastaurinNeurologicalOncologyPain TherapeuticsPfizerPharmaceuticalRegulationRemoxyResearch

Hospira returns Posidur rights to DURECT

02-04-2012

DURECT Corp (Nasdaq: DRRX) says that fellow USA-based that Hospira (NYSE: HSP) has given notice that…

DurectHospiraLicensingNeurologicalNorth AmericaPharmaceuticalPosidur

Company Spotlight

ImmunoGen

ImmunoGen

Back to top